---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-108983"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-09T23:56:38.988909+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SELLAS expects REGAL enrollment ex-China by Nov 2023; China start triggers $13M milestone

## Summary
- Enrollment outside China expected to complete in November 2023; patient numbers for interim and final analyses already enrolled.
- Interim analysis (60 events) on track for late 2023/early 2024; final analysis (80 events) targeted by end of 2024.
- China partner 3D Medicines to begin REGAL enrollment in Q4 2023, triggering two milestone payments totaling $13.0 million.
- 3D Medicines has obtained all regulatory permits and set up 11 treatment centers in China; previously projected Q3 start delayed by supply-chain issues.

## SEC filing metadata
- accession: 0001104659-23-108983
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465923108983/0001104659-23-108983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465923108983/tm2328393d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-108983
- JSON: https://secwatch.observer/filing/0001104659-23-108983.json
- Plain text: https://secwatch.observer/filing/0001104659-23-108983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.